Opalescence of an IgG1 Monoclonal Antibody Formulation is Mediated by Ionic Strength and Excipients - Can increase in ionic strength result in higher viscosity? - BioPharm International

ADVERTISEMENT

Opalescence of an IgG1 Monoclonal Antibody Formulation is Mediated by Ionic Strength and Excipients
Can increase in ionic strength result in higher viscosity?


BioPharm International
Volume 22, Issue 4

17. Winzor DJ, Deszczynski M, Harding SE, Wills PR. Nonequivalence of second virial coefficients from sedimentation equilibrium and static light scattering studies of protein solutions. Biophys Chem. 2007;128:46–55.

18. Bajaj H, Sharma VK, Badkar A, Zeng D, Nema S, Kalonia DS. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution. Pharm Res. 2006;23:1382–94.

19. George A, Wilson WW. Predicting protein crystallization from a dilute solution property. Acta Crystallogr D Biol Crystallogr. 1994;50:3–5.

20. Valente JJ, Verma KS, Manning MC, Wilson WW, Henry CS. Second virial coefficient studies of cosolvent-induced protein self-interaction. Biophys J. 2005;89:4211–8.

21. Shi L, Sanyal G, Ni A et al. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci. 2005;94:1538–51.

22. Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 2005;94:1928–40.

23. Baldwin RL. How Hofmeister ion interactions affect protein stability. Biophys J. 1996;71:2056–63.

24. Ionescu RM, Shi L. Thermal unfolding of proteins. The encylopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. 2008. John Wiley & Sons, Inc. In Press.

25. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci. 2008;97:1414–26.

26. Payne RW, Nayar R, Tarantino R et al. Second virial coefficient determination of a therapeutic peptide by self-interaction chromatography. Biopolymers. 2006;84:527–33.

27. Rosenbaum DF, Zukoski CF. Protein interactions and crystallization. J Crystal Growth. 1996;169:752–8.

28. Moore JM, Patapoff TW, Cromwell ME. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochem. 1999;38:13960–7.

29. Kameoka D, Masuzaki E, Ueda T, Imoto T. Effect of buffer species on the unfolding and the aggregation of humanized IgG. J Biochem. 2007;142:383–91.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here